Skip to main content

Ionis Pharmaceuticals, Inc. (IONS)

NASDAQ: IONS · IEX Real-Time Price · USD
29.81
-0.63 (-2.07%)
After-hours:Oct 22, 2021 6:38 PM EDT
30.44
0.11 (0.36%)
At close: Oct 22, 4:00 PM
Market Cap4.30B
Revenue (ttm)687.72M
Net Income (ttm)-541.96M
Shares Out140.96M
EPS (ttm)-3.97
PE Ration/a
Forward PE90.91
Dividendn/a
Ex-Dividend Daten/a
Volume753,383
Open30.20
Previous Close30.33
Day's Range29.81 - 30.53
52-Week Range29.01 - 64.37
Beta1.13
AnalystsBuy
Price Target54.94 (+80.5%)
Est. Earnings DateNov 3, 2021

About IONS

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It is involved in developing neurology products that include Tominersen for Huntington's diseases; Tofersen for amyotrophic lateral sclero...

IndustryBiotechnology
IPO DateMay 17, 1991
CEOBrett Monia
Employees757
Stock ExchangeNASDAQ
Ticker SymbolIONS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 20 analysts, the average rating for IONS stock is "Buy." The 12-month stock price forecast is 54.94, which is an increase of 80.49% from the latest price.

Price Target
$54.94
(80.49% upside)
Analyst Consensus: Buy

News

Why Ionis Pharmaceuticals Stock Is Down 13% This Week

An experimental treatment for amyotrophic lateral sclerosis missed the mark in a phase 3 trial.

1 day ago - The Motley Fool

Ionis to hold third quarter 2021 financial results webcast

CARLSBAD, Calif., Oct. 20, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, November 3 rd at 11:30 a.m.

3 days ago - PRNewsWire

What's Next For Ionis Pharmaceuticals Stock After A 14% Fall?

The stock price of Ionis Pharmaceuticals, a biotech company that specializes in discovering and developing RNA-targeted therapeutics, plunged 14% in yesterday's trade to its five year low levels of $30,...

3 days ago - Forbes

Ionis' partner Biogen provides update on tofersen Phase 3 VALOR study in SOD1-ALS

CARLSBAD, Calif., Oct. 17, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) partner Biogen today announced topline results from its placebo-controlled pivotal Phase 3 VALOR study of tofer...

5 days ago - PRNewsWire

3 Stocks to Consider if the October Stock Market Sell-Off Worsens

These stocks could be attractive at discounted prices.

Other symbols:AVIRMRK
6 days ago - The Motley Fool

3 Biotech Stocks With Huge Catalysts This Fall

Clinical trial results expected this fall could send shares of these stocks screaming higher, or lower.

Other symbols:CMPSNBIX
3 weeks ago - The Motley Fool

Ionis Pharmaceuticals (IONS) Up 3% Since Last Earnings Report: Can It Continue?

Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock?

1 month ago - Zacks Investment Research

Ionis to host ATTR symposium highlighting CARDIO-TTRansform Study at 3rd European ATTR Amyloidosis meeting

CARLSBAD, Calif., Sept. 3, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapies, announced today it will present 14 posters and two symposiums highlighti...

1 month ago - PRNewsWire

Ionis to present at upcoming virtual investor conferences

CARLSBAD, Calif., Sept. 2, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will present a company overview at the following virtual investor conferences: ...

1 month ago - PRNewsWire

Ionis (IONS) Q2 Earnings & Revenues Fall Short of Estimates

Ionis (IONS) incurs wider-than-expected Q2 loss. The company maintains its sales guidance for 2021 but expects to incur more losses.

2 months ago - Zacks Investment Research

Ionis Pharmaceuticals (IONS) Reports Q2 Loss, Lags Revenue Estimates

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of -1.79% and -9.17%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Ionis reports second quarter 2021 financial results and recent business achievements

CARLSBAD, Calif., Aug. 4, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported its financial results for the second quarter of 2021 and recent business achievements.

2 months ago - PRNewsWire

7 F-Rated Stocks to Avoid for the Rest of 2021

In a churning market like this, you want to steer clear of stocks that are floundering. Here are sevens stocks to avoid today.

2 months ago - InvestorPlace

Ionis completes enrollment in pivotal NEURO-TTRansform study of eplontersen

CARLSBAD, Calif., July 29, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapies, today announced it has completed enrollment of NEURO-TTRansform, the com...

2 months ago - PRNewsWire

Analysts Estimate Ionis Pharmaceuticals (IONS) to Report a Decline in Earnings: What to Look Out for

Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

5 Mid-Cap Healthcare Stocks You'll Want on Your Radar for the 2nd Half of 2021

These biotech stocks could have great long-term potential.

Other symbols:EDITIGMSXNCRZYME
3 months ago - The Motley Fool

Ionis to hold second quarter 2021 financial results webcast

CARLSBAD, Calif., July 21, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, August 4 th at 11:30 a.m.

3 months ago - PRNewsWire

Ionis (IONS) Inks Deal With Bicycle Therapeutics for LICA Drugs

Ionis (IONS) signs a deal with Bicycle Therapeutics to incorporate the latter's optimized Bicycle peptides into its LICA delivery platform.

Other symbols:BCYC
3 months ago - Zacks Investment Research

Bicycle, Ionis To Develop Targeted Oligonucleotide Therapeutics

Bicycle Therapeutics plc (NASDAQ: BCYC) announced that Ionis Pharmaceuticals Inc (NASDAQ: IONS) has exercised its option and entered into an exclusive worldwide license and collaboration agreement to de...

Other symbols:BCYC
3 months ago - Benzinga

Ionis enters exclusive licensing agreement with Bicycle Therapeutics aimed at further advancing LICA technology

CARLSBAD, Calif., July 13, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that it has entered into an exclusive licensing agreement with Bicycle Therapeutics plc (NASDAQ...

Other symbols:BCYC
3 months ago - PRNewsWire

3 Cathie Wood Stocks You Can Buy for Less Than $50

You can get a lot of bang for the buck with these picks.

Other symbols:PACBSKLZ
3 months ago - The Motley Fool

New Strong Sell Stocks for July 8th

CLPR, IONS, RAD, TFFP, and VNCE have been added to the Zacks Rank #5 (Strong Sell) List on July 8, 2021

Other symbols:CLPRRADTFFPVNCE
3 months ago - Zacks Investment Research

Can These 2 Beaten-Down Biotechs Rebound? Cathie Wood Thinks So.

Recent trial disappointments scared off some investors.

Other symbols:VRTX
3 months ago - The Motley Fool

Ionis Pharmaceuticals Stock Looks Attractive At $37

We believe that the stock price of Ionis Pharmaceuticals, a biotech company that specializes in discovering and developing RNA-targeted therapeutics, is undervalued at current levels of under $37. IONS ...

4 months ago - Forbes